BioMarin Pharmaceutical Inc. (BMRN)
Automate Your Wheel Strategy on BMRN
With Tiblio's Option Bot, you can configure your own wheel strategy including BMRN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BMRN
- Rev/Share 16.1119
- Book/Share 31.5401
- PB 1.8266
- Debt/Equity 0.1009
- CurrentRatio 4.8276
- ROIC 0.069
- MktCap 11067707358.0
- FreeCF/Share 4.3293
- PFCF 13.3127
- PE 21.2579
- Debt/Assets 0.0803
- DivYield 0
- ROE 0.0884
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | BMRN | Barclays | -- | Overweight | -- | $80 | Jan. 28, 2026 |
| Upgrade | BMRN | Canaccord Genuity | Hold | Buy | -- | $98 | Jan. 20, 2026 |
| Downgrade | BMRN | Leerink Partners | Outperform | Market Perform | -- | $60 | Dec. 3, 2025 |
| Downgrade | BMRN | Stifel | Buy | Hold | -- | $61 | Nov. 6, 2025 |
| Initiation | BMRN | H.C. Wainwright | -- | Neutral | -- | $60 | Sept. 8, 2025 |
| Initiation | BMRN | Raymond James | -- | Outperform | -- | $85 | Sept. 3, 2025 |
| Resumed | BMRN | Morgan Stanley | -- | Overweight | -- | $97 | July 3, 2025 |
| Upgrade | BMRN | Oppenheimer | Perform | Outperform | -- | $98 | Feb. 24, 2025 |
| Resumed | BMRN | Raymond James | -- | Outperform | -- | $79 | Oct. 10, 2024 |
| Upgrade | BMRN | Bernstein | Market Perform | Outperform | $94 | $110 | Aug. 20, 2024 |
News
Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term
Published: January 16, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Buy These 5 Price-to-Book Value Stocks for Gains in 2026
Published: January 15, 2026 by: Zacks Investment Research
Sentiment: Positive
Five low price-to-book stocks stand out for 2026, as undervalued valuations and solid growth outlooks put them on investors' radar.
Read More
4 Value Stocks to Buy As Wall Street Weighs Trump Policies
Published: January 14, 2026 by: Zacks Investment Research
Sentiment: Positive
As markets reel from policy uncertainty, UHS, PNC, GPN, and BMRN emerge as compelling value picks with strong cash flow.
Read More
BMRN or TARS: Which Is the Better Value Stock Right Now?
Published: January 13, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with BioMarin Pharmaceutical (BMRN) and Tarsus Pharmaceuticals, Inc. (TARS). But which of these two stocks is more attractive to value investors?
Read More
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
Published: January 13, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Is BioMarin Pharmaceutical (BMRN) a Great Value Stock Right Now?
Published: January 13, 2026 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
Published: January 12, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD
Published: December 26, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Amicus Therapeutics, Inc. (NasdaqGM: FOLD) to BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN). Under the terms of the proposed transaction, shareholders of Amicus will receive $14.50 in cash for each share of Amicus that they own. KSF is seeking to determine whether this consideration and the process.
Read More
BioMarin: Amicus Buyout Sparks My Enthusiasm
Published: December 22, 2025 by: Seeking Alpha
Sentiment: Positive
BioMarin, along with Sanofi, is a leader in the rare disease therapeutics market. It has an extensive portfolio of enzyme replacement therapies, including Palynziq, Vimizim, and Brineura. For example, sales of Brineura, approved for CLN2 disease, reached $48 million in Q3, up 29.7% year-on-year.
Read More
BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Positive
BMRN agrees to acquire FOLD for $4.8B, adding two growing rare disease drugs and a late-stage pipeline asset to its portfolio.
Read More
BioMarin Pharmaceutical Inc. (BMRN) M&A Call Transcript
Published: December 19, 2025 by: Seeking Alpha
Sentiment: Neutral
BioMarin Pharmaceutical Inc. (BMRN) M&A Call Transcript
Read More
BioMarin Pharmaceutical Inc. (BMRN) Presents at Jefferies London Healthcare Conference 2025 Transcript
Published: November 18, 2025 by: Seeking Alpha
Sentiment: Neutral
BioMarin Pharmaceutical Inc. ( BMRN ) Jefferies London Healthcare Conference 2025 November 18, 2025 5:30 AM EST Company Participants Alexander Hardy - President, CEO & Director Brian Mueller - Executive VP of Finance, CFO & Principal Accounting Officer Gregory Friberg - Executive VP and Chief Research & Development Officer Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Presentation Akash Tewari Jefferies LLC, Research Division Day 2 of our London Healthcare Conference. Great to see everyone.
Read More
BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England
Published: November 11, 2025 by: PRNewsWire
Sentiment: Neutral
SAN RAFAEL, Calif. , Nov. 11, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England in London.
Read More
FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria
Published: October 29, 2025 by: PRNewsWire
Sentiment: Neutral
Application based on positive results from Phase 3 PEGASUS study, which demonstrated statistically significant blood phenylalanine (Phe) lowering compared to diet alone FDA PDUFA target action date of Feb. 28, 2026 SAN RAFAEL, Calif. , Oct. 29, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the company's PALYNZIQ ® (pegvaliase-pqpz) supplemental Biologics License Application (sBLA) to expand treatment to include adolescents aged 12-17 with phenylketonuria (PKU).
Read More
BioMarin Beats on Q3 Earnings, Seeks to Divest Hemophilia Gene Therapy
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Positive
BMRN tops Q3 earnings expectations but misses on sales. The company moves to divest its hemophilia gene therapy, Roctavian.
Read More
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
Published: October 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
BioMarin: Valuation, Growth, And The Pipeline May Outweigh TransCon Competition And Regulatory Risks
Published: September 30, 2025 by: Seeking Alpha
Sentiment: Neutral
BioMarin has both a solid revenue portfolio of several products and a promising pipeline. The market's main concern has been TransCon competition; however, the combination of Voxzogo and BMN 333 could effectively fight back. Even if the U.S. government were to regulate prices, it would only affect a small portion of the company, since 64% of its sales originate outside the US.
Read More
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
Published: September 19, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
BioMarin Pharmaceutical Inc. (BMRN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)
Published: September 04, 2025 by: Seeking Alpha
Sentiment: Neutral
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 8:45 AM EDT Company Participants Gregory Friberg - Executive VP and Chief Research & Development Officer Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Mohit Bansal Senior Equity Analyst All right. Thank you very much for joining us today.
Read More
BioMarin Pharmaceutical Inc. (BMRN) Presents At Cantor Global Healthcare Conference 2025 Transcript
Published: September 03, 2025 by: Seeking Alpha
Sentiment: Neutral
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Cantor Global Healthcare Conference 2025 September 3, 2025 8:00 AM EDT Company Participants Gregory Friberg - Executive VP and Chief Research & Development Officer Conference Call Participants Olivia Brayer - Cantor Fitzgerald & Co., Research Division Presentation Olivia Brayer Research Analyst Okay. Great. Hey, good morning, everyone.
Read More
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
Published: August 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
BioMarin to Participate in Upcoming Investor Conferences
Published: August 27, 2025 by: PRNewsWire
Sentiment: Neutral
Cantor Global Healthcare Conference, September 3 at 8:00 am EST Wells Fargo Healthcare Conference, September 4 at 8:45 am EST Morgan Stanley Global Healthcare Conference, September 9 at 11:30 am EST SAN RAFAEL, Calif. , Aug. 27, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at upcoming investor conferences in September.
Read More
BioMarin Pharmaceutical (BMRN) is a Top-Ranked Momentum Stock: Should You Buy?
Published: August 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
Published: August 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
Published: August 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
BioMarin Beats on Q2 Earnings & Sales, Stock Gains on Raised '25 View
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
BMRN's Q2 earnings surge 50% on strong Voxzogo and enzyme therapy sales, prompting a raised 2025 revenue and EPS outlook.
Read More
BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Looking for a Growth Stock? 3 Reasons Why BioMarin (BMRN) is a Solid Choice
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Positive
BioMarin (BMRN) possesses solid growth attributes, which could help it handily outperform the market.
Read More
About BioMarin Pharmaceutical Inc. (BMRN)
- IPO Date 1999-07-26
- Website https://www.biomarin.com
- Industry Biotechnology
- CEO Alexander Hardy
- Employees 3040